Quoin Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Quoin Pharmaceuticals, Inc.

Jun-04	Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome QNRX GlobeNewswire
Jun-02	Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome QNRX GlobeNewswire
May-07	Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results QNRX GlobeNewswire
Apr-30	Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 QNRX +9.27% GlobeNewswire
Apr-28	CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs QNRX +8.81% QNRX GlobeNewswire
Apr-28	Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs QNRX GlobeNewswire
Mar-26	Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results QNRX -18.39% GlobeNewswire
Mar-25	Quoin Pharmaceuticals Provides Clinical and Regulatory Update from Constructive Type C Meeting with U.S. FDA for QRX003 in Netherton Syndrome QNRX +15.88% GlobeNewswire
Mar-19	Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 QNRX +5.36% GlobeNewswire
Mar-11	Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome QNRX GlobeNewswire
Feb-26	NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome QNRX GlobeNewswire
Jan-27	Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome QNRX GlobeNewswire
Nov-11	Quoin Pharmaceuticals Announces Achievement of Topical Rapamycin Target Loadings for Two Proprietary Delivery Technologies QNRX +41.40% GlobeNewswire
Nov-06	Quoin Pharmaceuticals Announces Corporate Update and Third Quarter 2025 Financial Results QNRX -11.19% GlobeNewswire
Oct-30	Quoin Pharmaceuticals to Provide Corporate Update and Announce Third Quarter 2025 Financial Results on Thursday, November 6, 2025 QNRX -7.15% GlobeNewswire
Oct-28	Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month 'Whole Body' Data Update from Ongoing Study QNRX GlobeNewswire
Oct-21	Quoin Pharmaceuticals Announces U.S. FDA Grants Orphan Drug Designation for QRX003 in Netherton Syndrome QNRX GlobeNewswire
Oct-10	Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million QNRX +151.23% GlobeNewswire
Sep-09	Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome QNRX GlobeNewswire
Aug-21	Quoin Pharmaceuticals' NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome QNRX GlobeNewswire
Aug-18	Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy QNRX GlobeNewswire
Aug-12	Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton QNRX GlobeNewswire
Aug-07	Quoin Pharmaceuticals Announces Second Quarter 2025 Financial Results and Corporate Update QNRX -6.24% GlobeNewswire
Jul-31	Quoin Pharmaceuticals to Announce Second Quarter 2025 Financial Results on Thursday, August 7, 2025 QNRX -12.36% GlobeNewswire
Jul-29	Quoin Pharmaceuticals Provides Product Portfolio Update QNRX GlobeNewswire
Jun-26	Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases QNRX GlobeNewswire
Jun-24	Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome QNRX GlobeNewswire
May-22	Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study QNRX GlobeNewswire
May-20	Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome QNRX +6.01% GlobeNewswire
May-14	Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study QNRX +20.28% GlobeNewswire
May-13	Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results QNRX GlobeNewswire
May-06	Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025 QNRX GlobeNewswire

Quoin Pharmaceuticals, Inc.

Recent Articles by Quoin Pharmaceuticals, Inc.

Upgrade your Finviz experience